Payment overview · 2025
General Payments
$1,421.07
53 reported records · 17 companies
Healthcare provider profile · identity verified
Mark D. Le, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TOMBALL, TX · NPI 1033153002
Verified facts
What the public records show
CMS Open Payments records show Mark D. Le, M.D. received $1,421.07 in general payments during 2025 across 53 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $343.29 | 24.2% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $238.39 | 16.8% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $164.75 | 11.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.43 | 8.1% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $114.36 | 8.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $100.67 | 7.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.16 | 3.7% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $47.80 | 3.4% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $46.30 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.36 | 3.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.44 | 2.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.06 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.54 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.46 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.83 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.65 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.58 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,353.12 | 52 |
| Education | $67.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $282.00 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $238.39 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $206.07 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $189.98 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $164.75 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.43 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $114.43 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $100.67 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.16 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $47.80 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.41 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $46.30 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.83 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 30 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 208 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
208 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 422 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 101 |
| Gabapentin | Gabapentin | 274 | 101 |
| Lisinopril | Lisinopril | 263 | 84 |
| Losartan Potassium | Losartan Potassium | 261 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 70 |
| Tramadol Hcl | Tramadol Hcl | 249 | 70 |
| Ezetimibe | Ezetimibe | 216 | 76 |
| Ozempic | Semaglutide | 208 | 51 |
| Trazodone Hcl | Trazodone Hcl | 190 | 71 |
| Potassium Chloride | Potassium Chloride | 187 | 66 |
| Metformin Hcl | Metformin Hcl | 175 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 68 |
| Fenofibrate | Fenofibrate | 168 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 164 | 70 |
| Furosemide | Furosemide | 153 | 54 |
| Meloxicam | Meloxicam | 129 | 47 |
| Clonidine Hcl | Clonidine Hcl | 128 | 60 |
| Glipizide | Glipizide | 123 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 121 | 43 |
| Metformin Hcl Er | Metformin Hcl | 114 | 47 |
| Simvastatin | Simvastatin | 95 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 25 |
| Azithromycin | Azithromycin | 92 | 76 |
| Alendronate Sodium | Alendronate Sodium | 91 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 26 |
| Carvedilol | Carvedilol | 89 | 30 |
| Atenolol | Atenolol | 86 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 28 |
| Sertraline Hcl | Sertraline Hcl | 85 | 32 |
| Omeprazole | Omeprazole | 82 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 31 |
| Cephalexin | Cephalexin | 79 | 62 |
| Clonazepam | Clonazepam | 77 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 37 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 73 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 63 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 32 |
| Buspirone Hcl | Buspirone Hcl | 64 | 23 |
| Prednisone | Prednisone | 59 | 45 |
| Donepezil Hcl | Donepezil Hcl | 57 | 23 |
| Meclizine Hcl | Meclizine Hcl | 56 | 31 |
| Mounjaro | Tirzepatide | 55 | 11 |
| Finasteride | Finasteride | 52 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 14 |
| Amoxicillin | Amoxicillin | 43 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | 14 |
| Montelukast Sodium | Montelukast Sodium | 42 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 12 |
| Ondansetron Odt | Ondansetron | 39 | 30 |
| Methylprednisolone | Methylprednisolone | 38 | 36 |
| Nifedipine Er | Nifedipine | 38 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 12 |
| Farxiga | Dapagliflozin Propanediol | 36 | 11 |
| Pregabalin | Pregabalin | 36 | 12 |
| Valsartan | Valsartan | 36 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 14 |
| Allopurinol | Allopurinol | 33 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Nystatin | Nystatin | 32 | 14 |
| Topiramate | Topiramate | 32 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Eliquis | Apixaban | 30 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 16 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 14 |
| Lorazepam | Lorazepam | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 11 |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 12 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 13 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,421.07 · 53 records | AstraZeneca Pharmaceuticals LP | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, AREXVY, Axonics, BREZTRI, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error